ArriVent Biopharma: Funding, Investors & Team (Oct 2026)
ArriVent is a biopharmaceutical company developing pharmaceutical products to cure presently untreatable cancer.
ArriVent Biopharma has raised $569M across 4 funding rounds on record, the most recent an undisclosed round of $250M announced in May 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ArriVent Biopharma Company Profile and Key Stats
Latest funding round on record: May 2026.
ArriVent Biopharma Funding Rounds
ArriVent Biopharma raised $69.0M in a Series A announced in Feb 2022.
1.9 years later, an undisclosed round of $175M was announced in Jan 2024.
1.5 years later, an undisclosed round of $75.0M was announced in Jul 2025.
10 months later, an undisclosed round of $250M was announced in May 2026.
ArriVent Biopharma Founders and Leadership Team
Contact details for the ArriVent Biopharma team: 2 of 3 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →ArriVent Biopharma Funding Compared to Other Biotechnology Startups
ArriVent Biopharma's latest round of $250M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ArriVent Biopharma in Biotechnology and Pennsylvania Furnace
Companies Similar to ArriVent Biopharma
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…
ArriVent Biopharma Funding FAQs
What does ArriVent Biopharma do?
ArriVent is a biopharmaceutical company developing pharmaceutical products to cure presently untreatable cancer.
How much funding has ArriVent Biopharma raised?
ArriVent Biopharma has raised $569M across 4 rounds on record. The most recent is an undisclosed round of $250M announced in May 2026.
When did ArriVent Biopharma last raise funding?
ArriVent Biopharma's most recent funding round on record is an undisclosed round of $250M, announced in May 2026.
Who founded ArriVent Biopharma?
FundedIQ lists Bing Yao (Founder), Stuart Lutzker (Founder), Zhengbin (bing) (Founder) at ArriVent Biopharma.
Where is ArriVent Biopharma headquartered?
ArriVent Biopharma is based in Pennsylvania Furnace, Pennsylvania, United States.
How many employees does ArriVent Biopharma have?
ArriVent Biopharma is in the 51-100 employee band.
How does ArriVent Biopharma's funding compare to other Biotechnology startups?
ArriVent Biopharma's latest round of $250M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's ArriVent Biopharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ArriVent Biopharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.